ATAI enters Friday's earnings print with the short-side capitulation that defined the August 11–13 preview now running even deeper — and a fresh options signal adding a new wrinkle.
Short interest has continued its retreat since the previous articles. From a peak near 38 million shares in early July, shorts now hold roughly 15.4 million — 7.2% of the free float, down another 8% in the latest session and 44% below where it was a week ago. The borrow market confirms the exodus: availability has expanded to 2,184% — more than double last week's already-loose 999% reading — meaning there are now roughly 22 shares available to lend for every one currently borrowed. Cost to borrow has eased further to 0.41%, down 27% on the week. The ORTEX short score has dropped to 36.6, its lowest point in the observable history here, down from 40.4 at the time of the last earnings-preview article. Bears have not merely stood aside — they have largely left the building.
Options positioning has tightened in the other direction, and the contrast is now sharper than it was. The put/call ratio hit 0.275 on Tuesday — its highest reading in the past 52 weeks — running nearly two standard deviations above the 20-day mean of 0.234. That is a meaningful shift from the mild z-score of roughly 0.5 noted in the August 12 trader note. Call volume still dominates absolute terms, but the relative drift toward puts is the most pronounced it has been all year. The stock itself is essentially unchanged, up just over 1% on the week to $7.29, having absorbed the Lilly deal news and the downgrade wave without breaking lower.
The analyst community remains a headwind. The coordinated downgrade wave in mid-July — six firms cutting from Buy to Hold in a single week — was followed by Deutsche Bank's August 12 downgrade and target cut to $8. The consensus now sits firmly at Hold, with just one Buy rating surviving among 14 analysts. The mean price target of $8.10 implies modest upside from current levels. Bulls point to BPL-003's Phase 3 progression and the Eli Lilly transaction as validation of the pipeline's value; bears counter that the $2.8 billion acquisition price came in below prior Street targets and effectively caps near-term upside for shareholders while transferring the real commercial upside to Lilly. That tension — deal validation versus deal ceiling — is the central debate the print will have to address.
The institutional register adds one genuinely interesting data point: BlackRock added 18.7 million shares in its most recent filing, making it the second-largest holder at 6.9% of shares. State Street also built a new position of 7.1 million shares in the same period. That passive-plus-active accumulation at the institutional level sits awkwardly beside the analyst consensus retreat — and Thursday's print is the first chance for the company to close the gap between those two signals.
See the live data behind this article on ORTEX.
Open ATAI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
